Search: WFRF:(Jonsson Hans) >
The impact of a new...
-
Carlsten, Hans,1954Gothenburg University,Göteborgs universitet,Institutionen för invärtesmedicin, Avdelningen för reumatologi och inflammationsforskning,Institute of Internal Medicine, Dept of Rheumatology and Inflammation Research
(author)
The impact of a new immunomodulator oxo-quinoline-3-carboxamide on the progression of experimental lupus
- Article/chapterEnglish2004
Publisher, publication year, extent ...
Numbers
-
LIBRIS-ID:oai:gup.ub.gu.se/51082
-
https://gup.ub.gu.se/publication/51082URI
-
https://doi.org/10.1016/j.intimp.2004.07.009DOI
Supplementary language notes
Part of subdatabase
Classification
-
Subject category:ref swepub-contenttype
-
Subject category:art swepub-publicationtype
Notes
-
Autoimmune, lupus-prone MRL lpr/lpr mice were treated orally with oxo-quinoline-3-carboxamide (ABR-25757), a newly developed immunomodulator. Treatment was initiated in one set of experiment at the age of 10 weeks, before the onset of clinically apparent disease, and in another set at 15 weeks, after the development of established lupus disease. Beneficial therapeutic effects were obtained even when ABR-25757 was administered at the lowest dose tested (7.5 microg/mouse/week) to 15 weeks old mice with established lupus disease. The effects of ABR-25757 on longevity, as well as on development of glomerulonephritis were pronounced and comparable with those of LS-2616, a potent immunomodulator. Administration of ABR-25757 did not significantly alter T cell responses in vivo nor in vitro. In addition, it only marginally suppressed B cell responses measured as frequencies of immunoglobulin secreting cells. By the same token this compound did not affect overall leukocyte content in primary (bone marrow) or secondary (spleen) lymphoid tissues. In contrast, treatment with ABR-25757 up regulated expression of pro-inflammatory transcription factors NF-kappaB and AP-1. These results suggest (a) a potential therapeutic role of ABR-25757 in the treatment of experimental lupus and (b) that the effect of the treatment is mediated by immunodeviation rather than by immunosuppression.
Subject headings and genre
-
Animals
-
Disease Models
-
Animal
-
Female
-
Immunity
-
Natural/drug effects
-
Immunoglobulins/immunology
-
Immunologic Factors/*therapeutic use
-
Lupus Erythematosus
-
Systemic/*drug therapy/immunology
-
Lymphocyte Activation/drug effects/immunology
-
Male
-
Mice
-
Mice
-
Inbred MRL lpr
-
Quinolones/*therapeutic use
-
T-Lymphocytes/drug effects/immunology
-
Transcription Factors/immunology
Added entries (persons, corporate bodies, meetings, titles ...)
-
Jonsson, Charlotte A,1971Gothenburg University,Göteborgs universitet,Institutionen för invärtesmedicin, Avdelningen för reumatologi och inflammationsforskning,Institute of Internal Medicine, Dept of Rheumatology and Inflammation Research(Swepub:gu)xjonch
(author)
-
Bokarewa, Maria,1963Gothenburg University,Göteborgs universitet,Institutionen för invärtesmedicin, Avdelningen för reumatologi och inflammationsforskning,Institute of Internal Medicine, Dept of Rheumatology and Inflammation Research(Swepub:gu)xbokma
(author)
-
Svensson, Lena,1958Gothenburg University,Göteborgs universitet,Institutionen för invärtesmedicin, Avdelningen för reumatologi och inflammationsforskning,Institute of Internal Medicine, Dept of Rheumatology and Inflammation Research
(author)
-
Tarkowski, Andrej,1951Gothenburg University,Göteborgs universitet,Institutionen för invärtesmedicin, Avdelningen för reumatologi och inflammationsforskning,Institute of Internal Medicine, Dept of Rheumatology and Inflammation Research(Swepub:gu)xtaand
(author)
-
Göteborgs universitetInstitutionen för invärtesmedicin, Avdelningen för reumatologi och inflammationsforskning
(creator_code:org_t)
Related titles
-
In:Int Immunopharmacol: Elsevier BV4:12, s. 1515-231567-5769
Internet link
Find in a library
To the university's database